CONTEXT: Symptoms of fluid retention in GH-deficient patients during GH replacement are greater in men than in women, suggesting that testosterone may augment or estradiol may attenuate the antinatriuretic actions of GH. The mechanisms underlying the sodium-retaining effects of GH are poorly understood. AIM: The aim of this study was to investigate the effects of GH and testosterone, alone and in combination, on extracellular water (ECW) and the hormonal mechanisms involved. DESIGN: Two separate, open-label, randomized, two-period, crossover studies were performed; the first compared the effects of GH alone with those of GH and testosterone, and the second compared the effects of testosterone alone with those of GH and testosterone. PARTICIPANTS: Twelve hypopituitary men with GH deficiency and hypogonadism were studied. INTERVENTION: During the weeks of intervention, GH (0.5 mg/d) and testosterone enanthate (250 mg) were administered by im injection. OUTCOME MEASURES: The outcome measures were ECW, IGF-I, plasma renin activity (PRA), aldosterone (Aldo), and atrial natriuretic peptide (ANP). RESULTS:GH treatment significantly increased (P < 0.05) both IGF-I and ECW, and these changes were enhanced by cotreatment with testosterone (P = 0.07 for both). PRA, Aldo, and ANP levels did not change. Testosterone treatment alone did not change the IGF-I concentration, whereas cotreatment with GH induced a marked increase. Testosterone alone increased (P < 0.05) ECW, and the effect was augmented (P < 0.01) by cotreatment with GH. Although PRA and ANP did not change, plasma Aldo decreased after single and combined treatments. CONCLUSION:GH and testosterone exerted independent and additive effects on ECW. The mechanisms of fluid retention for both hormones are likely to be exerted on the renal tubules. This is the first direct evidence that testosterone increases ECW.
RCT Entities:
CONTEXT: Symptoms of fluid retention in GH-deficientpatients during GH replacement are greater in men than in women, suggesting that testosterone may augment or estradiol may attenuate the antinatriuretic actions of GH. The mechanisms underlying the sodium-retaining effects of GH are poorly understood. AIM: The aim of this study was to investigate the effects of GH and testosterone, alone and in combination, on extracellular water (ECW) and the hormonal mechanisms involved. DESIGN: Two separate, open-label, randomized, two-period, crossover studies were performed; the first compared the effects of GH alone with those of GH and testosterone, and the second compared the effects of testosterone alone with those of GH and testosterone. PARTICIPANTS: Twelve hypopituitary men with GH deficiency and hypogonadism were studied. INTERVENTION: During the weeks of intervention, GH (0.5 mg/d) and testosterone enanthate (250 mg) were administered by im injection. OUTCOME MEASURES: The outcome measures were ECW, IGF-I, plasma renin activity (PRA), aldosterone (Aldo), and atrial natriuretic peptide (ANP). RESULTS: GH treatment significantly increased (P < 0.05) both IGF-I and ECW, and these changes were enhanced by cotreatment with testosterone (P = 0.07 for both). PRA, Aldo, and ANP levels did not change. Testosterone treatment alone did not change the IGF-I concentration, whereas cotreatment with GH induced a marked increase. Testosterone alone increased (P < 0.05) ECW, and the effect was augmented (P < 0.01) by cotreatment with GH. Although PRA and ANP did not change, plasma Aldo decreased after single and combined treatments. CONCLUSION: GH and testosterone exerted independent and additive effects on ECW. The mechanisms of fluid retention for both hormones are likely to be exerted on the renal tubules. This is the first direct evidence that testosterone increases ECW.
Authors: Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda Journal: Pituitary Date: 2015-12 Impact factor: 4.107
Authors: T Gagliano-Jucá; E R Tang; S Bhasin; K M Pencina; S Anderson; H Jara; Z Li; K Melamud; S L Coleman; A Aakil; R R Almeida; G Huang; T G Travison; T W Storer; S Basaria Journal: Andrology Date: 2017-07-13 Impact factor: 3.842
Authors: Carlos M Reyes-Vidal; Hamed Mojahed; Wei Shen; Zhezhen Jin; Fernando Arias-Mendoza; Jean Carlos Fernandez; Dympna Gallagher; Jeffrey N Bruce; Kalmon D Post; Pamela U Freda Journal: J Clin Endocrinol Metab Date: 2015-06-02 Impact factor: 5.958
Authors: Shehzad Basaria; Andrea D Coviello; Thomas G Travison; Thomas W Storer; Wildon R Farwell; Alan M Jette; Richard Eder; Sharon Tennstedt; Jagadish Ulloor; Anqi Zhang; Karen Choong; Kishore M Lakshman; Norman A Mazer; Renee Miciek; Joanne Krasnoff; Ayan Elmi; Philip E Knapp; Brad Brooks; Erica Appleman; Sheetal Aggarwal; Geeta Bhasin; Leif Hede-Brierley; Ashmeet Bhatia; Lauren Collins; Nathan LeBrasseur; Louis D Fiore; Shalender Bhasin Journal: N Engl J Med Date: 2010-06-30 Impact factor: 91.245
Authors: Jacques Baillargeon; Randall J Urban; Yong-Fang Kuo; Kenneth J Ottenbacher; Mukaila A Raji; Fei Du; Yu-Li Lin; James S Goodwin Journal: Ann Pharmacother Date: 2014-07-02 Impact factor: 3.154
Authors: E Todd Schroeder; Jiaxiu He; Kevin E Yarasheski; Ellen F Binder; Carmen Castaneda-Sceppa; Shalender Bhasin; Christina M Dieli-Conwright; Miwa Kawakubo; Ronenn Roubenoff; Stanley P Azen; Fred R Sattler Journal: Eur J Appl Physiol Date: 2011-07-12 Impact factor: 3.078
Authors: Peter Kamenicky; Say Viengchareun; Anne Blanchard; Geri Meduri; Philippe Zizzari; Martine Imbert-Teboul; Alain Doucet; Philippe Chanson; Marc Lombès Journal: Endocrinology Date: 2008-04-03 Impact factor: 4.736